-98.3%
DFNS vs MRNA
+485.7%
-584.0%
-99.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.5% | +5.4% | -7.9% | -2.8% |
| 7D | -6.3% | -1.1% | -5.3% | -6.3% |
| 30D | -74.0% | +126.1% | -200.1% | -75.2% |
| 3M | -70.1% | +190.0% | -260.2% | -71.3% |
| 6M | -93.9% | +157.2% | -251.1% | -94.1% |
| YTD | -98.1% | +388.2% | -486.3% | -98.2% |
| 1Y | -98.3% | +467.0% | -565.3% | -98.4% |
| All | -98.3% | +485.7% | -584.0% | -98.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling